Please login to the form below
Bispecific antibody
This page shows the latest Bispecific antibody news and features for those working in and with pharma, biotech and healthcare.
Genentech reports positive phase 3 data for its Tecentriq combination in liver cancer
cancers. In December 2022, its bispecific antibody, Lunsumio (mosunetuzumab-axgb), was approved by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more
Latest news
-
Moderna and CytomX to partner in deal worth up to 1.2bn
CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.
-
Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab
Biogen has reached an agreement with Genentech – a member of the Roche group – on the potential commercialisation of the investigational bispecific antibody, glofitamab, as part of the companies’ long-standing collaboration ... it the first and
-
Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma
inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. ... Elranatamab is an investigational, humanised B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), which targets both BCMA-expressing multiple myeloma
-
Summit Therapeutics partners with Akeso in deal worth $5bn
Summit Therapeutics (Summit) has announced a definitive agreement of its partnership with Akeso in a deal worth up to $5bn to in-licence its breakthrough bispecific antibody, ivonescimab. ... Recently presented phase 2 study results showed the PD-1/ VEGF
-
Regeneron and CytomX partner to create conditional bispecific cancer therapies
CytomX's pipeline currently comprises seven therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies and immune modulators such as cytokines and checkpoint inhibitors.
More from news
Approximately 6 fully matching, plus 61 partially matching documents found.
Latest Intelligence
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Finally, in multiple myeloma, a first-in-class bispecific T-cell engager antibody – talquetamab – is showing promise in heavily pre-treated patients.
-
ASH 2022: bad blood but big advances
One particular session on bispecific antibodies attracted huge interest, requiring multiple separate overflow areas to accommodate the crowds. ... relapsed multiple myeloma with talquetamab – a GPRC5D x CD3 bispecific antibody.
-
Unlocking the potential of precision medicine in oncology
We are following a similar approach in lung cancer through an ongoing partnership to pursue a molecular diagnostic strategy for our early-stage investigational EGFR-MET bispecific antibody, which is being
-
European biotech: a new generation of leaders emerges
In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In addition to traditional antibodies, the pipeline also includes antibody drug
-
Deal Watch December 2016
5, 500. Merus Labs (Canada). Incyte (US). Discovery collaboration. Biclonics bispecific antibody technology for up to 11 research programmes, including 2 in immuno-oncology. ... Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early
-
New hires at FibroGen, Saniona and Turbine
Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.
-
F-star hires ex-BMS immuno-oncology leader
Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent
-
F-star appoints GSK's Neil Brewis
Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. ... This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
- Europe’s cancer community publishes new report on transforming patient care
- Assessing the value of interim analyses in clinical trials
- Piloting a route to the biosimilars opportunities in Europe
- Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
